Sparing Bone Marrow in Patients with Stage IIB-IV Lung Cancer, VMAT Trial
Sparing Bone Marrow in Patients with Stage IIB-IV Lung Cancer, VMAT Trial
This phase II trial tests whether designing radiation to avoid bone marrow in the spine (vertebral bone marrow) leads to less reduction of white blood cell counts (lymphopenia) in patients with lung cancer. This sparing technique could lead to better disease control and outcome.
Lung
N/A
Adults
Not Available
Not Available
Osmundson, Evan
National
Vanderbilt University
10-05-2022
Eligibility
18 Years
BOTH
NO
Inclusion Criteria:
Adult patient >= 18 years
Patients with non-small cell lung cancer (NSCLC): American Joint Committee on Cancer (AJCC) 8 T0-T4, N1-N3, M0 stage IIB, IIIA-IIIC or oligometastatic disease stage IV, M1 disease, in which concurrent chemoradiotherapy to the thorax is planned with or without adjuvant immunotherapy
Patients with oligometastatic disease stage IV, M1 disease, in which definitive concurrent chemoradiotherapy to the thorax is planned
Absolute lymphocyte count > 0.8 K/uL
Hemoglobin > 8 g/dL
Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) 2.5 times of upper limits of normal (ULN)
Eastern Cooperative Oncology Group (ECOG) 0-2
Exclusion Criteria:
History of thoracic irradiation
History of palliative radiation for the current malignancy under consideration
Patients not being treated with a curative approach to the chest
History of bone marrow disease and or leukemia
History of prior cytotoxic chemotherapy for a disease other than for the current malignancy
Polymetastatic disease, defined here as >= 3 or more extrathoracic metastases
Administration of concurrent immunotherapy during radiation therapy, either as part of another clinical trial or otherwise
Adult patient >= 18 years
Patients with non-small cell lung cancer (NSCLC): American Joint Committee on Cancer (AJCC) 8 T0-T4, N1-N3, M0 stage IIB, IIIA-IIIC or oligometastatic disease stage IV, M1 disease, in which concurrent chemoradiotherapy to the thorax is planned with or without adjuvant immunotherapy
Patients with oligometastatic disease stage IV, M1 disease, in which definitive concurrent chemoradiotherapy to the thorax is planned
Absolute lymphocyte count > 0.8 K/uL
Hemoglobin > 8 g/dL
Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) 2.5 times of upper limits of normal (ULN)
Eastern Cooperative Oncology Group (ECOG) 0-2
Exclusion Criteria:
History of thoracic irradiation
History of palliative radiation for the current malignancy under consideration
Patients not being treated with a curative approach to the chest
History of bone marrow disease and or leukemia
History of prior cytotoxic chemotherapy for a disease other than for the current malignancy
Polymetastatic disease, defined here as >= 3 or more extrathoracic metastases
Administration of concurrent immunotherapy during radiation therapy, either as part of another clinical trial or otherwise
